The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

被引：0
|
作者：
Kai Rejeski
Doris K. Hansen
Radhika Bansal
Pierre Sesques
Sikander Ailawadhi
Jennifer M. Logue
Eva Bräunlein
David M. Cordas dos Santos
Ciara L. Freeman
Melissa Alsina
Sebastian Theurich
Yucai Wang
Angela M. Krackhardt
Frederick L. Locke
Emmanuel Bachy
Michael D. Jain
Yi Lin
Marion Subklewe
机构：
[1] LMU Munich,Department of Medicine III – Hematology/Oncology, LMU University Hospital
[2] LMU Gene Center,Laboratory for Translational Cancer Immunology
[3] German Cancer Consortium (DKTK),Department of Blood and Marrow Transplant and Cellular Immunotherapy
[4] Munich Site,Division of Hematology
[5] and German Cancer Research Center,Division of Hematology and Oncology
[6] Bavarian Cancer Research Center (BZKF),IIIrd Medical Department, Klinikum rechts der Isar and Center for Translational Cancer Research (TranslaTUM), School of Medicine
[7] Moffitt Cancer Center,Department of Medicine I
[8] Mayo Clinic,undefined
[9] Hospices Civils de Lyon,undefined
[10] Université Claude Bernard Lyon 1,undefined
[11] INSERM 1052,undefined
[12] Mayo Clinic,undefined
[13] Technical University of Munich,undefined
[14] Malteser Hospital St. Franziskus Hospital,undefined
来源：
Journal of Hematology & Oncology | / 16卷
关键词：
Chimeric antigen receptor; BCMA CAR-T; Hematological toxicity; Cytopenias; Multiple myeloma; Infections;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
    Rejeski, Kai
    Hansen, Doris K.
    Bansal, Radhika
    Sesques, Pierre
    Ailawadhi, Sikander
    Logue, Jennifer M.
    Braeunlein, Eva
    dos Santos, David M. Cordas M.
    Freeman, Ciara L.
    Alsina, Melissa
    Theurich, Sebastian
    Wang, Yucai
    Krackhardt, Angela M.
    Locke, Frederick L.
    Bachy, Emmanuel
    Jain, Michael D.
    Lin, Yi
    Subklewe, Marion
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [2] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
    Feng, Deming
    Sun, Jian
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
  • [3] CAR-T Therapy in Relapsed Refractory Multiple Myeloma
    Ding, Hong
    Wu, Yu
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (27) : 4362 - 4382
  • [4] CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity
    Krejci, Martin
    Adam, Zdenek
    Krejci, Marta
    Pour, Ludek
    Sandecka, Viera
    Stork, Martin
    NEOPLASMA, 2022, 69 (05) : 1008 - 1018
  • [5] Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
    Li, Hujun
    Zhao, Lina
    Sun, Zengtian
    Yao, Yue
    Li, Li
    Wang, Jiaojiao
    Hua, Tian
    Ji, Shengwei
    Wang, Shiyuan
    Cheng, Hai
    Shi, Ming
    Li, Zhenyu
    Zeng, Lingyu
    Wu, Qingyun
    Qiao, Jianlin
    Chen, Chong
    Zheng, Junnian
    Cao, Jiang
    Xu, Kailin
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma
    Chen, Zihan
    Chen, Yegan
    Liu, Jiaying
    Sun, Yingjun
    Zhang, Xiaoxue
    Shao, Lingyan
    Wang, Dandan
    Wang, Xue
    Chen, Wei
    Sang, Wei
    Qi, Kunming
    Li, Zhenyu
    Sun, Cai
    Shi, Ming
    Qiao, Jianlin
    Wu, Qingyun
    Zeng, Lingyu
    Zheng, Junnian
    Xu, Kailin
    Li, Li
    Cheng, Hai
    Cao, Jiang
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025,
  • [7] Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
    Su, Christopher T.
    Ye, J. Christine
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [8] Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
    Christopher T. Su
    J. Christine Ye
    Journal of Hematology & Oncology, 14
  • [9] BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement
    Wang, Yiyun
    Zu, Cheng
    Teng, Xinyi
    Yang, Li
    Zhang, Mingming
    Hong, Ruimin
    Zhao, Houli
    Cui, Jiazhen
    Xu, Huijun
    Hongsheng, Alex Chang
    Hu, Yongxian
    Huang, He
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (01) : 25 - 34
  • [10] Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma
    Martin, Thomas G.
    Madduri, Deepu
    Pacaud, Lida
    Usmani, Saad Z.
    FUTURE ONCOLOGY, 2023, 19 (34) : 2297 - 2311
12345